$TCRT
Alaunos Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023020088 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $4.000K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.045M $3.168M $3.505M
YoY Change -11.2% -9.61% -57.4%
% of Gross Profit
Research & Development $5.186M $6.504M $5.580M
YoY Change -12.65% 16.56% -58.16%
% of Gross Profit
Depreciation & Amortization $699.0K $696.0K $689.0K
YoY Change 2.04% 1.02% 27.59%
% of Gross Profit
Operating Expenses $7.986M $9.672M $9.085M
YoY Change -13.51% 6.46% -57.87%
Operating Profit -$7.982M -$9.672M -$9.085M
YoY Change -13.55% 6.46% -57.87%
Interest Expense $1.068M $853.0K -$683.0K
YoY Change 44.32% -224.89%
% of Operating Profit
Other Income/Expense, Net -$791.0K -$376.0K -$703.0K
YoY Change -2029.27% -46.51% -7911.11%
Pretax Income -$8.773M -$10.05M -$9.788M
YoY Change -11.67% 2.66% -54.59%
Income Tax
% Of Pretax Income
Net Earnings -$8.773M -$10.05M -$9.788M
YoY Change -11.67% 2.66% -54.59%
Net Earnings / Revenue -219325.0%
Basic Earnings Per Share -$0.04 -$0.04 -$0.05
Diluted Earnings Per Share -$0.04 -$0.04 -$45.54K
COMMON SHARES
Basic Shares Outstanding 240.6M 240.6M 216.1M
Diluted Shares Outstanding 239.8M 239.7M 214.9M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.32M $23.50M $68.26M
YoY Change -69.48% -65.58% -31.78%
Cash & Equivalents $18.32M $23.50M $68.30M
Short-Term Investments
Other Short-Term Assets $457.0K $14.69M $1.517M
YoY Change -66.15% 868.23% -80.16%
Inventory
Prepaid Expenses
Receivables $4.000K $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.78M $38.18M $69.77M
YoY Change -69.4% -45.27% -38.1%
LONG-TERM ASSETS
Property, Plant & Equipment $7.214M $7.889M $10.31M
YoY Change -25.41% -23.49% -33.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K $626.0K
YoY Change 0.0% -20.13% 98.73%
Total Long-Term Assets $9.149M $10.45M $15.22M
YoY Change -27.22% -31.31% -3.44%
TOTAL ASSETS
Total Short-Term Assets $18.78M $38.18M $69.77M
Total Long-Term Assets $9.149M $10.45M $15.22M
Total Assets $27.93M $48.64M $84.99M
YoY Change -62.23% -42.77% -33.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.479M $1.380M $605.0K
YoY Change 212.03% 128.1% -85.56%
Accrued Expenses $3.234M $4.120M $5.891M
YoY Change -43.51% -30.06% -60.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $10.99M $13.99M
YoY Change -100.0% -21.48%
Total Short-Term Liabilities $5.052M $17.06M $21.23M
YoY Change -81.13% -19.64% 11.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $10.32M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $28.00K $4.312M
YoY Change -100.0% -99.35% 11.42%
Total Long-Term Liabilities $0.00 $28.00K $10.32M
YoY Change -100.0% -99.73% 166.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.052M $17.06M $21.23M
Total Long-Term Liabilities $0.00 $28.00K $10.32M
Total Liabilities $6.277M $19.13M $35.87M
YoY Change -81.4% -46.67% 57.11%
SHAREHOLDERS EQUITY
Retained Earnings -$899.4M -$890.7M -$852.6M
YoY Change 4.27% 4.47%
Common Stock $921.1M $920.2M $901.8M
YoY Change 2.03% 2.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.65M $29.51M $49.12M
YoY Change
Total Liabilities & Shareholders Equity $27.93M $48.64M $84.99M
YoY Change -62.23% -42.77% -33.84%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.773M -$10.05M -$9.788M
YoY Change -11.67% 2.66% -54.59%
Depreciation, Depletion And Amortization $699.0K $696.0K $689.0K
YoY Change 2.04% 1.02% 27.59%
Cash From Operating Activities -$7.002M -$9.381M -$7.770M
YoY Change -14.47% 20.73% -49.26%
INVESTING ACTIVITIES
Capital Expenditures $135.0K $61.00K $29.00K
YoY Change -336.84% 110.34% -95.96%
Acquisitions
YoY Change
Other Investing Activities $0.00 $38.00K
YoY Change
Cash From Investing Activities -$135.0K -$23.00K -$29.00K
YoY Change 136.84% -20.69% -95.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $6.250M $0.00
YoY Change
Cash From Financing Activities -11.98M -6.158M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -7.002M -9.381M -7.770M
Cash From Investing Activities -135.0K -23.00K -29.00K
Cash From Financing Activities -11.98M -6.158M 0.000
Net Change In Cash -19.12M -15.56M -7.799M
YoY Change 131.89% 99.54% -48.05%
FREE CASH FLOW
Cash From Operating Activities -$7.002M -$9.381M -$7.770M
Capital Expenditures $135.0K $61.00K $29.00K
Free Cash Flow -$7.137M -$9.442M -$7.799M
YoY Change -12.21% 21.07% -51.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-33038
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
8030 El Rio Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
CY2023Q1 dei City Area Code
CityAreaCode
346
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
355-4099
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
TCRT
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
240627055
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23496000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39058000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
13938000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
13938000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
0
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
750000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
799000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
38184000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
53799000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7889000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8460000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2023000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2136000
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2023Q1 us-gaap Assets
Assets
48638000
CY2022Q4 us-gaap Assets
Assets
64937000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1380000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1389000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
10988000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
16765000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4120000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5454000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
575000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
558000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
17063000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24166000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2038000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2188000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2023Q1 us-gaap Liabilities
Liabilities
19129000
CY2022Q4 us-gaap Liabilities
Liabilities
26382000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
420000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
240627055
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
240627055
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
420000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
240410761
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
240410761
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
241000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
240000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
919943000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
918942000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-890675000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-880627000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
29509000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38555000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48638000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64937000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6504000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5580000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3168000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3505000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
9672000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
9085000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9672000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9085000
CY2023Q1 us-gaap Interest Expense
InterestExpense
853000
CY2022Q1 us-gaap Interest Expense
InterestExpense
683000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
477000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-376000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-703000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10048000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9788000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
239679352
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
239679352
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214946569
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214946569
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38555000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
910000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10048000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
29509000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
853000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9788000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
49122000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10048000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9788000
CY2023Q1 us-gaap Depreciation
Depreciation
696000
CY2022Q1 us-gaap Depreciation
Depreciation
689000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
472000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
198000
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
910000
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
853000
CY2023Q1 tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-113000
CY2022Q1 tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-180000
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1111000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-49000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-149000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-5000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-110000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-763000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1334000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-214000
CY2023Q1 tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-133000
CY2022Q1 tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-190000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9381000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7770000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
61000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
38000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6250000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6158000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15562000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7799000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52996000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76054000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37434000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68255000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
439000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
484000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
101000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37400000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
13900000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-890700000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10988000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16765000
CY2021Q3 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.045
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
900000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
700000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37133713
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34885875
CY2023Q1 tcrt Lease Termination Date
LeaseTerminationDate
2023-04-19
CY2023Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
a term to June 30, 2025 with an option to extend through July 31, 2026
CY2023Q2 tcrt Sublease Term Commenced End Date Amendment
SubleaseTermCommencedEndDateAmendment
2026-07-31
CY2023Q1 tcrt Termination Costs
TerminationCosts
200000
CY2018Q4 tcrt Maximum Royalty Amount
MaximumRoyaltyAmount
100000000.0
CY2023Q1 us-gaap Royalty Expense
RoyaltyExpense
0
CY2022Q1 us-gaap Royalty Expense
RoyaltyExpense
0
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y11M26D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3891598
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.46
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y29D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
12555464
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
910000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
853000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3065168
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2690000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0358
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0387
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0163
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0243
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8969
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9563
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7449
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7627
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10408622
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.84
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3065168
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.52
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
160544
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.90
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13313246
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.54
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
364000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4553574
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.31
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-020088-index-headers.html Edgar Link pending
0000950170-23-020088-index.html Edgar Link pending
0000950170-23-020088.txt Edgar Link pending
0000950170-23-020088-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img42087188_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20230331.htm Edgar Link pending
tcrt-20230331.xsd Edgar Link pending
tcrt-ex10_1.htm Edgar Link pending
tcrt-ex10_2.htm Edgar Link pending
tcrt-ex10_3.htm Edgar Link pending
tcrt-ex10_4.htm Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending
tcrt-20230331_def.xml Edgar Link unprocessable
tcrt-20230331_cal.xml Edgar Link unprocessable
tcrt-20230331_lab.xml Edgar Link unprocessable
tcrt-20230331_pre.xml Edgar Link unprocessable
tcrt-20230331_htm.xml Edgar Link completed